pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›cemdisiran
drug · oligonucleotide
save

cemdisiran

pre_registrationupdated 6mo ago
by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes

Oligonucleotide drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.

targets

Complement C5 mRNA

all catalysts(0)

nothing on the calendar yet

Trials studying cemdisiran

  • phase3A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophyrecruitingn=975
  • phase3A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Worksrecruitingn=202
  • phase3A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficientlyrecruitingn=35
  • phase3A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravisactive not recruitingn=288
  • phase3A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatmentactive not recruitingn=202
  • EP1Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositisrecruitingn=10
  • —Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuriano longer available
  • phase2Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapycompletedn=6

News(4)

  • Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
    The go-ahead for Alnylam Pharmaceuticals–partnered Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
    biospace · 4h ago
  • With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
    The product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
    biopharma_dive · 4h ago
  • Regeneron enters neurology field as FDA approves siRNA for myasthenia gravis
    Regeneron’s siRNA therapy cemdisiran has become the second new drug approved by the FDA for myasthenia gravis inside of a week. Now named Livsayis, the therapy was approved by the FDA for ...
    endpoints · 4h ago
  • Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
    Regeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…
    biospace · 20d ago
generic
cemdisiran
MOA
Complement C5 mRNA RNAi inhibitor
indication
Myasthenia Gravis
phase
pre_registration
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 3m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?